CoreWeave's $129 Billion Backlog Meets Its Toughest Test: Turning Contracts Into Cash
Super Micro's $72–82 Billion AI Bet Meets a Wall Street Divide
PepsiCo Cuts 2026 Profit Growth Guidance as Gatorade Powder Push Tests Demand
Deutsche Bank's Cost Puzzle Overshadows a Lifted Revenue Bar
BMW's Zero-Margin Tightrope: Brokers Slash Targets but Refuse to Abandon Ship
DWS Sits Between a Bull and a Bear as Property Fund Curbs Add a Third Variable
AMD's Record Data-Center Quarter Is Already Banked — Wall Street Is Now Arguing About the Multiple
Redcare Pharmacy Wins on Prescriptions but Pays for It in the Share Price
Rocket Lab's 16% Jump Came With the Crowd — the November 9 Print Will Show If It Can Stand Alone
Nokia Charts AI's Network Future From Japan to North Carolina as Shares Rebound 3.5%
Atlassian's $4.75 Billion Backlog Meets a Slower Cloud: Inside the 15% Slide
Silver's Physical Cushion Meets the Fed's Shadow
SK Hynix's Locked-In Order Book Faces a Washington Stress Test
SAP's €2 Billion AI Efficiency Drive Collides With a Global Tech Retreat
Rheinmetall's Shadow and a Record Backlog: Hensoldt's Split-Screen Quarter
Leonardo Lifts Order Target to €29.5 Billion but Leaves Profit Guidance Untouched
RWE Fires Up 34 MW Hydrogen-Capable Turbine in Lingen as BlackRock Trims Stake to 7.12%
Microsoft Tightens Grip on Third-Party AI Capacity as IREN's January Deadline Looms
Siemens Energy: A 3.8% Gain, Two Reaffirmed Bull Calls and the Low Bar Set for 11 November
Teradyne's India Opportunity and Robotics Bet Test Investor Patience
Logitech Faces a Two-Front Test: Supplier Disruption and a Marketing Firestorm
Rio Tinto Restarts Oyu Tolgoi Underground Work as Copper Sentiment Sours
Andritz Balances Order Dip With Revenue Growth as New Projects Come Online
Equinox Gold Heads Into November 9 Results With a Bigger Production Base and a Sector Tailwind
UPM-Kymmene Insider Purchase Masks Underlying Earnings Pressure
Partners Group Splits €6.6 Billion Fund Into Old and New Pools as Withdrawal Requests Pile Up
Lumentum's 6.6% Rebound Masks a Harder Question: What Are Marvell Shares Actually Worth?
J&J's Oral Psoriasis Drug Clears Late-Stage Hurdle as Orthopedics Deal Talks Collapse
Lumentum's Stock-Swap Math Now Ties Its Fate to Marvell's Share Price
BAT Slides With London Market as Boardroom Changes and a Goldman Upgrade Draw Focus